Long-Term Impact of Vutrisiran in Patients With TTR Amyloidosis With Cardiomyopathy: 1-Year Efficacy and Safety Outcomes From the HELIOS-B Open-Label Extension
Source: View publication →
In the 1-year open-label extension of the HELIOS-B trial, early and continuous treatment with vutrisiran demonstrated sustained reductions in mortality and cardiovascular events compared to delayed treatment, highlighting the irreversible consequences of delaying RNAi therapy in ATTR-CM.
Key Findings
Study Design
Study Limitations
Clinical Significance
These long-term findings solidify vutrisiran as a foundational disease-modifying therapy for ATTR-CM, demonstrating that sustained transthyretin knockdown yields expanding survival and cardiovascular benefits over time. Crucially, the delayed-start analysis confirms that waiting to initiate therapy results in irreversible disease progression and functional decline, underscoring the necessity of early diagnosis and prompt treatment initiation.
Historical Context
Historically, ATTR-CM was an untreatable and rapidly fatal disease. The introduction of the TTR stabilizer tafamidis (ATTR-ACT, 2018) revolutionized care but left a need for more potent therapies. Vutrisiran's primary HELIOS-B trial (2024) was a landmark event, proving that a subcutaneously administered RNAi significantly improved survival and cardiovascular outcomes in ATTR-CM. This 2026 open-label extension builds on those results by confirming the long-term durability of these survival benefits and establishing the critical importance of early intervention due to irreversible functional losses when therapy is delayed.
Guided Discussion
High-yield insights from every perspective
How does the mechanism of action of RNA interference (RNAi) therapies like vutrisiran explain the finding that delayed treatment in ATTR-CM leads to irreversible cardiovascular consequences compared to early treatment?
Key Response
Vutrisiran works by degrading TTR mRNA in the liver, preventing the synthesis of both mutant and wild-type TTR protein. It halts new amyloid deposition but does not actively clear existing amyloid fibrils from the myocardium. Therefore, any structural myocardial damage, extracellular matrix expansion, and fibrosis that occurs during a delay in treatment is irreversible, emphasizing the critical need for early diagnosis and intervention before permanent remodeling occurs.
Given the HELIOS-B OLE findings that delayed initiation of vutrisiran results in worse long-term mortality, what specific clinical 'red flags' should prompt you to suspect ATTR-CM in a patient with HFpEF to minimize diagnostic delay?
Key Response
Because delayed treatment leads to permanent myocardial injury, residents must quickly recognize extracardiac manifestations like bilateral carpal tunnel syndrome, lumbar spinal stenosis, spontaneous biceps tendon rupture, and peripheral neuropathies, alongside echocardiographic findings like disproportionate apical sparing. Early recognition expedites non-invasive diagnosis via PYP scan and allows immediate initiation of disease-modifying therapies like vutrisiran.
The HELIOS-B extension highlights the divergence in outcomes between early and delayed vutrisiran. For a patient already demonstrating clinical progression on a TTR stabilizer like tafamidis, how does the pathophysiological rationale for transitioning to a silencer like vutrisiran align with these findings?
Key Response
Stabilizers prevent TTR tetramer dissociation but do not stop TTR production, whereas silencers like vutrisiran halt production entirely. If a patient progresses on tafamidis, ongoing tetramer instability and amyloid deposition are likely occurring. The study's emphasis on the 'irreversible consequences of delay' suggests that subclinical progression on a stabilizer warrants prompt transition to a silencer before irreversible myocardial fibrosis accumulates further.
The 'irreversible consequences' of delaying RNAi therapy in ATTR-CM challenge the traditional step-up approaches in heart failure. How should this data reshape our health system pathways and payer negotiations for high-cost therapies?
Key Response
This study mandates a paradigm shift from reactive to proactive treatment in ATTR-CM. Attendings must advocate for streamlined diagnostic algorithms (e.g., EMR triggers for PYP scans) and use this comparative efficacy data to aggressively negotiate with payers for immediate RNAi approval. Delaying therapy for step-up trials (e.g., mandating failure of a stabilizer first) directly translates to preventable mortality and irreversible structural decline.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In analyzing the 1-year open-label extension of HELIOS-B, how should researchers control for survivorship bias and the 'healthy worker' effect, given that placebo patients who survived to enter the OLE might represent a less severe cohort?
Key Response
In open-label extensions where the placebo arm crosses over, the sickest placebo patients often die or drop out before the extension phase. This attrition bias artificially enriches the delayed-treatment arm with robust patients, potentially underestimating the true magnitude of harm caused by delayed therapy. Advanced statistical models, such as inverse probability of censoring weighting (IPCW) or joint modeling of longitudinal and survival data, are essential to accurately estimate the true treatment effect.
As a reviewer evaluating this open-label extension, what are the primary threats to internal validity regarding the reporting of subjective cardiovascular events, such as heart failure hospitalizations, when transitioning from a double-blind to an open-label format?
Key Response
The shift to an open-label design introduces expectation bias. Investigators and patients knowing they are receiving active vutrisiran might alter their threshold for reporting symptoms or deciding on admission, particularly for the delayed group newly receiving the active drug. A rigorous review would scrutinize the blinding of the clinical events committee (CEC) and demand sensitivity analyses comparing objective endpoints (mortality) versus subjective ones (HF hospitalizations).
Current ACC/AHA/HFSA guidelines provide a Class 1 recommendation for tafamidis in select patients with ATTR-CM but lack long-term mortality data to position RNAi therapies as first-line alternatives. Based on the HELIOS-B OLE mortality data, what specific modifications to the treatment algorithm are warranted?
Key Response
Existing guidelines position tafamidis as the primary evidence-based therapy (Class 1, LOE B-R). The demonstration of sustained mortality reduction and the severe penalty of delayed treatment with vutrisiran in HELIOS-B provides the robust evidence necessary to elevate TTR silencers to a Class 1 (LOE A or B-R) recommendation for first-line therapy. This warrants an update that places vutrisiran alongside or ahead of stabilizers depending on patient phenotype, emphasizing immediate initiation upon diagnosis.
Clinical Landscape
Noteworthy Related Trials
ATTR-ACT Trial
Tested
Tafamidis 80mg or 20mg daily
Population
Patients with wild-type or variant ATTR-CM
Comparator
Placebo
Endpoint
All-cause mortality and cardiovascular hospitalizations
APOLLO-B Trial
Tested
Patisiran 0.3 mg/kg IV every 3 weeks
Population
Patients with ATTR-CM
Comparator
Placebo
Endpoint
Change in 6-minute walk distance at 12 months
HELIOS-A Trial
Tested
Vutrisiran 25 mg SC every 3 months
Population
Patients with hereditary ATTR amyloidosis with polyneuropathy
Comparator
External placebo from APOLLO trial
Endpoint
Change in modified Neuropathy Impairment Score +7 at 9 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis